Genelux Corporation
NASDAQ:GNLXBiotechnology
+$0.08 today
- Market cap
- $107.66M
- Beta
- 0.55
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.98
Volume 0.80M
Average 0.19M
GNLX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Genelux CorporationNASDAQ: GNLX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization turns negative
Q1 FY2026 depreciation & amortization was -$61K, compared with $139K a year earlier. Trailing-twelve-month depreciation & amortization was $44K. Over 3 fiscal years it compounded at -36.8% a year.
Context
- Depreciation & amortization amounted to 3050.0% of revenue in FY2025, down 8237.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near -$61K or moves back toward the trailing-twelve-month quarterly average of $11K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 244K USD
- Year-over-year change
- -73.0%
- 4-year CAGR
- -27.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 244K | -73.0% |
| FY2024 | 2024-12-31 | 903K | -11.3% |
| FY2023 | 2023-12-31 | 1.02M | +5.2% |
| FY2022 | 2022-12-31 | 968K | +8.2% |
| FY2021 | 2021-12-31 | 895K | — |
Depreciation & Amortization vs competitors
How GNLX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +116.9% is the highest of 9, against a peer median of +0.7%.
- Depreciation & amortization amounts to 550.0% of revenue for GNLX, versus a peer median of 96.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.68M USD | -2.6% | +3.0% | 28.9% | |
| LTM Mar 2026 | $10.43M USD | -42.2% | -11.2% | 33645.2% | |
| LTM Dec 2025 | CHF 2.5M CHF | +15.5% | +0.4% | 69.9% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.99M USD | -1.7% | -30.8% | — |
| LTM Dec 2025 | $1.23M USD | — | +8.0% | — | |
| LTM Mar 2026 | $1.18M USD | +9.0% | -11.2% | 236.0% | |
| LTM Mar 2026 | $885K USD | — | -2.3% | 96.0% | |
| LTM Mar 2026 | $749K USD | -23.9% | +2.8% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $328K USD | +19.3% | -0.6% | — |
| LTM Mar 2026 | $257.68K USD | +3.1% | -0.9% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $44K USD | +116.9% | -36.8% | 550.0% |
| Peer median (excluding GNLX) | — | +0.7% | -0.7% | 96.0% | |
Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (16.38M) | (5.21M) | (28.3M) | (29.87M) | (32.15M) |
| Depreciation & Amortization | 895K | 968K | 1.02M | 903K | 244K |
| Deferred Income Tax | 348K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.27M | 2.42M | 5.2M | 6.07M | 5.87M |
| Change in Working Capital | 4.08M | (1.69M) | (3.28M) | 751K | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 754K | 2.31M | (2.36M) | 2.16M | (1.21M) |
| Other Working Capital | 3.33M | (4M) | (923K) | (1.41M) | 167K |
| Other Non-Cash Items | 196K | (56K) | 5.08M | 917K | 1.81M |
| Operating Cash Flow | (6.59M) | (3.57M) | (20.28M) | (21.23M) | (25.27M) |
| Capital Expenditures | 0 | (49K) | (1.03M) | (381K) | (1.1M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (13.7M) | (29M) | (18.26M) |
| Sales of Investments | 0 | 0 | 0 | 21.25M | 31.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (49K) | (14.72M) | (8.13M) | 12.14M |
| Debt Repayment | (558K) | 970K | 215K | 0 | 0 |
| Common Stock Issued | 143K | 120K | 39.65M | 27.82M | 9.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 145K | (1.45M) | 4.16M | 688K | 0 |
| Financing Cash Flow | (270K) | (478K) | 44.02M | 28.51M | 9.9M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.86M) | (4.1M) | 9.02M | (853K) | (3.23M) |
| Free Cash Flow | (6.59M) | (3.62M) | (21.3M) | (21.61M) | (26.37M) |
Genelux Corporation
NASDAQ:GNLX
Intrinsic Alpha fair value
Locked
Current Price
$2.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.